• Hierachical and Programmable One-Pot Method Brings Oligosaccharide Synthesis to a Whole New Level

    One of the most important classes of biomolecules, oligosaccharides are involved in a variety of biochemical processes, including intercellular recognition, cell differentiation, cancer proliferation, inflammation and immune responses. In humans, carbohydrates... Read More
  • How Can You Mend a Broken Cell: Let Experimental Evolution Show You How

    When an essential car part dies, we expect the car dies as well. Same must also be true for the cell, so we think, because cell is akin to a hugely complicated “car”, in which many micro-machines work together under the hood to produce life. Well, one should know better. Here is a mind-boggling story regarding how cell manages, via the awesome power of evolution, to rescue itself from near death in the face of losing an indispensable gene (or “car part”). Read More
  • Aldolase - Metabolic Enzymes with Great Potentials for Cancer Theraputics

    The metabolic network plays an important role in homeostasis, which is a nature’s way of keeping everything balanced inside our bodies. In recent years, it has been discovered that within cancerous cells, the metabolic network is somehow tweaked. Read More
  • Collaborative Review Details Making Carbohydrates with “One-Pot” Strategies

    As one of the important classes of organic molecules, carbohydrates are considered a class of sophisticated and mysterious kind. As more and more brave pioneers tapped into this unknown region, various glyco-molecules, glyco-proteins and glyco-lipids are found to play important roles in cell growth and diseases... Read More
  • Promising HIV Vaccine Development Glycans Identified

    Since the first case of AIDS was diagnosed in 1981, more than 35 million people have died from the HIV/AIDS. Based on the statistics published by the Joint United Nations Programme on HIV/AIDS (UNAIDS), there were 36.7 million HIV carriers in 2016. Right now, around 2.5 million people die of AIDS each year, and there still lack treatments to effectively cure this disease... Read More
  • 1
  • 2
  • 3
  • 4
  • 5

Research in GRC Series


  • Dr. Tien-Hsien Chang To Receive the 2018-2019 Taiwan Rotary Charity Award
    Read More
  • Your effort has earned recognition, congratulations!
    Read More
  • Congratulations to Dr. Yun-Ru Chen for receiving the "Young Medical Scientist Awards" of the 14th TienTe Lee Biomedical Awards
    Read More
  • Congratulation to Dr. Wei-Shen Wu for getting the "Distinguished Thesis Awards" of the 14th TienTe Lee Biomedical Awards
    Read More

Research News

  • All
  • PopularScience
  • ResearchNews
  • Sugar intake in foods / Dr. Wen-Bin Yang
    Read More
    • PopularScience
  • CRISPR: God’s Scissors / Dr. Yu-Chi Chou
    Read More
    • PopularScience
  • Scientific Fortune Telling: Predicting Risk of Liver Cancer for Patients with Chronic Hepatitis B / Dr. Hwai-I Yang / 2013
    Read More
    • PopularScience
  • Making the right tools for tough jobs – how to build a scientific instrument / Dr. Yi-Sheng Wang
    Read More
    • PopularScience
  • Role of N-α-acetyltransferase 10 Protein in DNA Methylation and Genomic Imprinting
    Read More
    • ResearchNews
load more hold SHIFT key to load all load all

Chang, Tse Wen

ChangTW_6x7.jpgDistinguished Visiting Chair

Email: This email address is being protected from spambots. You need JavaScript enabled to view it.
Telephone: +886-2-27871252




  • B.S. & M.S., Chemistry, National Tsing Hua University, Taiwan, 1966-1972
  • Ph.D., Cell and Developmental Biology, Harvard University, 1973-1977
  • Postdoctoral Fellow, Center for Cancer Research, M. I. T., 1977-1980
  • Supervisor of Cellular Immunology, Ortho Pharmaceutical Corp., 1980-1981
  • Director of Immunology, V. P. of Research, Centocor, Inc., 1981-1985
  • Professor of Molecular Virology, Baylor College of Medicine, 1986-1991
  • Cofounder 1986, and V.P. of R & D, 1986-1996, Tanox, Inc., Houston
  • Professor 1996-2003; Dean 1996-1999; Tsing Hua Professor of Life Science 2003-2006; College of Life Science, National Tsing Hua University
  • President, Development Center for Biotechnology, Taipei, 2000-2003
  • Distinguished Research Fellow, Genomics Research Center, Academia Sinica, 2006-2015
  • Distinguished Visiting Chair, Genomics Research Center, Academia Sinica, 2016-present


  • Foundation for the Advancement of Outstanding Scholarship Award, 1997-2002
  • Appointed Science and Technology Advisor of the Executive Yuan, 2002-2006
  • Xolair (Chang's anti-IgE invention) approved by FDA, USA, 2003
  • Appointed Tsing Hua Professor of Life Science, 2003-2006
  • "Honorary Fellow Award" from American College of Allergy, Asthma, and Immunology (ACAAI), 2004
  • Nature Biotechnology's shortlist of personalities who made the most significant contribution to biotech in the past 10 years. Nature Biotechnology 24, 291-300, 2006
  • Xolair chosen for Prix Galien Award for outstanding innovation in R&D, UK, 2006
  • "Honorary Fellow Award" from American Academy of Allergy, Asthma, and Immunology (AAAAI), 2007
  • "Father of Xolair" plaque from Novartis, in Middle East Asthma and Allergy Conference, Dubai, 2012
  • "Lifetime Achievement Award in Allergy" from Taiwan Academy of Pediatric Allergy, Asthma and Clinical Immunology, 2013
  • TWAS(The World Academy of Sciences) Prize in Medical Sciences, 2014


New drug discovery and antibody engineering

The main focus of our group is to develop humanized antibody-based and immunogen-based therapeutics, which target key molecules involved in IgE-mediated allergic pathway. We are also developing new technology platforms for improved antibody engineering. One such program is to develop humanized antibody against CεmX domain in human membrane-bound IgE, for the purpose of controlling IgE-expressing B lymphocytes. CεmX, discovered by our group, is a 52 a.a. domain with a unique sequence. Anti-CεmX, if successfully developed, may be used in combination with an anti-IgE antibody, such as omalizumab (trade name Xolair), which is also derived from Dr. Chang's invention and which is approved for allergic asthma.



  • Chang TW, Chen C, Lin CJ, Metz M, Church MK, Maurer M, 2015, “The potential pharmacologic mechanisms of omalizumab in patients with chronic spontaneous urticaria.”, The Journal of allergy and clinical immunology, 135(2), 337-342.e2. (SCI)
  • Chu HM, Wright J, Chan YH, Lin CJ, Chang TW & Lim C, 2014, “Two potential therapeutic antibodies bind to a peptide segment of membrane-bound IgE in different conformations.”, Nature communications, 5, 3139. (SCI)
  • Chen JB, Wu PC, Hung AF, Chu CY, Tsai TF, Yu HM, Chang HY, Chang TW, 2010, “Unique epitopes on C epsilon mX in IgE-B cell receptors are potentially applicable for targeting IgE-committed B cells.”, Journal of immunology, 184(4), 1748-1756. (SCI)
  • Chang TW & Pan AY, 2008, “Cumulative environmental changes, skewed antigen exposure, and the increase of allergy.”, Advances in immunology, 98, 39-83. (SCI)
  • Chang TW, Wu PC, Hsu CL, Hung AF, 2007, “Anti-IgE antibodies for the treatment of IgE-mediated allergic diseases.”, Advances in immunology, 93, 63-119. (SCI)
  • Chang TW & Shiung YY, 2006, “Anti-IgE as a mast cell-stabilizing therapeutic agent.”, The Journal of allergy and clinical immunology, 117(6), 1203-1212. (SCI)
  • Chang TW, 2000, “The pharmacological basis of anti-IgE therapy.”, Nature biotechnology, 18(2), 157-162. (SCI)


Intranet Icon e

EmploymentIcon e

eln grcweb

Subsitute Service en


Seminars & Events



phdprograms en